The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
《每日生物技術脈搏》：布里斯托爾·邁爾斯、BridgeBio 簽署腫瘤學協議、FDA 點頭支持Lava Therapeutics血液癌研究等
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是過去 24 小時內生物技術領域的主要進展摘要：
Stocks In Focus
焦點股票
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
BridgeBio與Bristol Myers簽署了腫瘤學SHP2抑制劑的許可協議
BridgeBio Pharma Inc (NASDAQ:BBIO) has announced an exclusive license with Bristol Myers Squibb Co (NYSE:BMY) to develop and commercialize BBP-398 in oncology.
布里奇生物製藥公司（納斯達克股票代碼：BBIO）宣佈了獨家許可布里斯托爾邁爾斯施貴寶公司紐約證券交易所代碼：BMY）將在腫瘤學領域開發和商業化 BBP-398。
BridgeBio will receive an upfront payment of $90 million, up to $815 million in milestone payments and tiered royalties in the low- to mid-teens.
BridgeBio將獲得9000萬美元的預付款、高達8.15億美元的里程碑付款和低到中期的分級特許權使用費。
BridgeBio will retain the option to acquire higher royalties in the U.S. in connection with funding a portion of development costs upon the...
BridgeBio將保留在美國獲得更高特許權使用...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。